Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 1,881 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Renal Diseases Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

Acute Equol Supplementation and Vascular Function in Women With and Without CKD

NCT06128278
View directory record Official record
Conditions
Chronic Kidney Diseases, Vascular Function, Women
Interventions
S-equol, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 69 Years · Female only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Inflammation in Chronic Kidney Disease and Cardiovascular Disease - The Role of Genetics and Interleukin-1 Receptor Antagonist (IL-1ra)

NCT00897715
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 16, 2026, 10:05 PM EDT
Recruiting No phase listed Observational

Drug Interaction Potential of Pro-Inflammatory Conditions

NCT07360938
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
Interventions
None (Observational)
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

NCT01651000
View directory record Official record
Conditions
Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions
CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules
Drug · Other
Lead sponsor
OPKO IP Holdings II, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bannockburn, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease

NCT04067752
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
high dialysate sodium concentration (138 mEq/L), Low dialysate sodium concentration
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

NCT07165015
View directory record Official record
Conditions
Renal Impairment, Healthy, Renal Insufficiency, End Stage Renal Disease (ESRD)
Interventions
LY3537031
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Orlando, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic Hemodialysis

NCT01503021
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Kidney Disease
Interventions
SFP, Placebo
Drug · Other
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
28
States / cities
Mobile, Alabama • Northridge, California • Arvada, Colorado + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 16, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Examine Past Estimated Glomerular Filtration Rate (eGFR) Slope as a Risk Marker for Rapid Kidney Function Decline in People With Chronic Kidney Disease

NCT04881448
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
collection of serum/capillary creatinine values
Diagnostic Test
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
19
States / cities
Huntsville, Alabama • Victorville, California • Bloomfield, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 16, 2026, 10:05 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

iControl Chronic Kidney Disease

NCT03951363
View directory record Official record
Conditions
Chronic Kidney Diseases
Interventions
interactive Obesity Treatment Approach (iOTA)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Impact of a Personal Digital Assistant (PDA) - Based Dietary Adherence Intervention on Interdialytic Weight Gain and Blood Pressure in Hemodialysis Patients

NCT00447408
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Standard hemodialysis dietary instruction, Behavioral counseling plus PDA-based self-monitoring of diet
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Oct 16, 2026, 10:05 PM EDT
Withdrawn No phase listed Observational

Impact of Screening Patients With HIV for Kidney Disease

NCT00392132
View directory record Official record
Conditions
HIV Infections, Renal Insufficiency, Chronic, Proteinuria
Interventions
Not listed
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 16, 2026, 10:05 PM EDT
Active, not recruiting No phase listed Observational

Central Blood Pressure and Pulse Wave Velocity in Kidney Transplant Recipients

NCT04212143
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
there is no intervention
Other
Lead sponsor
Children's National Research Institute
Other
Eligibility
3 Years to 21 Years
Enrollment
150 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional

High-protein Oral Supplement Improves Normalized Protein Catabolic Rate and Inflammation Markers

NCT05227755
View directory record Official record
Conditions
Renal Failure, Chronic Kidney Disease Requiring Chronic Dialysis
Interventions
Soy protein isolate, Whey protein isolate
Dietary Supplement
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis

NCT00004340
View directory record Official record
Conditions
Renal Osteodystrophy, End Stage Renal Disease
Interventions
calcitriol, growth hormone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
1 Year to 18 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function

NCT03874117
View directory record Official record
Conditions
Hemodialysis, Kidney Failure, Chronic
Interventions
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis, Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Palo Alto, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo

NCT00915876
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Paricalcitol, Placebo
Drug
Lead sponsor
Amy Barton Pai
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 16, 2026, 10:05 PM EDT
Withdrawn Phase 4 Interventional

Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis Access

NCT04614142
View directory record Official record
Conditions
End Stage Renal Disease, Chronic Hepatitis c
Interventions
Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
34 Years to 44 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Supporting Self-Management of Healthy Behaviors in Chronic Kidney Disease

NCT04858295
View directory record Official record
Conditions
Renal Insufficiency, Chronic, Hypertension
Interventions
Texting, mHealth app
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 1 Interventional Results available

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

NCT03814005
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute, Renal Insufficiency, Liver Disease, Neoplasms
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
New York, New York • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)

NCT00501046
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Placebo, AST-120
Drug
Lead sponsor
Tanabe Pharma Corporation
Industry
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
46
States / cities
Tuscaloosa, Alabama • Hot Springs, Arkansas • Bakersfield, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Health Literacy 3D Kidney Model Patient Education Trial

NCT06683573
View directory record Official record
Conditions
High Blood Pressure, Kidney Disease, Chronic
Interventions
3D Kidney model, Standard medical treatment
Behavioral
Lead sponsor
Hilary L Surratt, PhD
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Renal Allograft Tolerance Through Mixed Chimerism

NCT01780454
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
MEDI-507, Rituximab, Total Body Irradiation, Thymic Irradiation
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 16, 2026, 10:05 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Enhancing the Natriuretic Peptide System in HFpEF

NCT05279742
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Chronic Kidney Diseases
Interventions
MANP, Sacubitril/Valsartan, Oral Placebo, Injection Placebo
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 16, 2026, 10:05 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

NCT00598273
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Darbepoetin alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
68
States / cities
Montgomery, Alabama • Tempe, Arizona • Hot Springs, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 16, 2026, 10:05 PM EDT